MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communic ...

Core Insights - PacBio has appointed David Ruggiero as the new Global Head of Sales & Service, effective February 10, 2025 [1][4] - Ruggiero has over 20 years of experience in sales leadership within technology and life sciences, previously serving in senior roles at companies like Sinch AB, Zoom Video Communications, Microsoft, and Thermo Fisher Scientific [2][3] - The company aims to expand its global presence and enhance customer support for its sequencing solutions under Ruggiero's leadership [3][4] Company Overview - Pacific Biosciences of California, Inc. (PacBio) is a leading life science technology company focused on advanced sequencing solutions [5] - The company offers two core technologies: HiFi long-read sequencing and SBB® short-read sequencing, addressing various research applications including human germline sequencing, oncology, and infectious disease [5] - PacBio products are designated for research use only and are not intended for diagnostic procedures [6]

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-88 ...

Core Insights - PacBio has appointed Chris Smith, CEO of NeoGenomics, to its Board of Directors, effective immediately, while David Meline steps down from the Board [1][4] - Chris Smith brings extensive experience in genomics, diagnostics, and corporate strategy, having led NeoGenomics in its growth and innovation in precision medicine [2][3] - The addition of Smith is expected to enhance PacBio's efforts to expand into the clinical genomics market, leveraging his expertise in clinical diagnostics [3][4] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions to address complex genetic problems [5] - The company utilizes two core technologies: HiFi long-read sequencing and SBB® short-read sequencing, applicable across various research fields including oncology, infectious disease, and microbiology [5] - PacBio's products are designated for research use only and are not intended for diagnostic procedures [6]

MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio's advanced sequencing solutions, including the synchronized Fiber-seq and Kinnex (formerly MAS-seq) multiomic approach, to uncover th ...

New sequencing approach resolves the genetic complexity of a rare Mendelian conditionMENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in Nature Genetics. The study, titled Synchronized long-read genome, methylome, epigenome, and transcriptome for resolving a Mendelian condition, showcases how researchers leveraged PacBio’s advanced sequencing solutions, including the ...

Core Insights - PacBio has announced the Global Institute for Food Security (GIFS) at the University of Saskatchewan as the first Revio PacBio Certified Service Provider in Canada, enhancing access to high-quality sequencing solutions [1][4][6] Company Overview - PacBio is a leading life science technology company focused on developing advanced sequencing solutions, including HiFi long-read and SBB short-read sequencing technologies, aimed at resolving genetically complex problems across various research applications [7] Service Provider Details - GIFS will utilize PacBio's HiFi sequencing technology through its Omics and Precision Analytics Laboratory (OPAL) platform, providing researchers with access to accurate long-read sequencing data for complex genetic studies [2][3] - The certification as a PacBio Certified Service Provider indicates that GIFS has the necessary expertise and infrastructure to deliver high-quality sequencing solutions, including genome assemblies and transcriptomics [3][4] Research and Development Impact - The partnership aims to support Canadian researchers in addressing global challenges such as food security and agricultural sustainability by providing them with advanced genomics solutions [4][5] - GIFS' OPAL platform offers full-service genomics solutions, including automation and advanced data analysis, positioning it as a valuable resource for large-scale genomic projects [4][5] Strategic Importance - The addition of GIFS to PacBio's Certified Service Provider network reflects the company's commitment to making its advanced sequencing solutions accessible to researchers globally [6]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent 2024 preliminary results and restructuring initiatives, is expected to contribute further. However, long purchasing cycles and business seasonality concerns persist.In the past six months, this Zacks Rank #3 (Hold) company’s shares have lost 8.1% against 4.8% growth of the industry. The S&P 500 Composite has also gained 9.4% in the said time frame.T ...

Pacific Biosciences of California, Inc. (PACB) recently announced a significant publication from Radboud University Medical Center (Radboudumc) and its research partners in the American Journal of Human Genetics.The study demonstrates the impact of PacBio’s HiFi long-read sequencing technology in identifying genetic causes of rare diseases, illustrating the feasibility of potentially replacing multiple diagnostic tests with a single, more comprehensive approach.(Read more: PacBio Stock May Gain Following th ...

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, recently shared its preliminary results for the fourth quarter and full year of 2024. Shares of PacBio closed 8% down on Jan. 14, as the top line missed market expectations.The company is scheduled to release fourth-quarter results on Feb. 15, 2025.Q4 Preliminary ResultsPacBio reported preliminary revenues of $39.2 million, down 33% year over year. The Zacks Consensus Estimate is pinned at $40.9 million.Consumable revenues are antic ...